⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 17 in last 7 days 🍎 Food: 0 in last 7 days 🧸 Products: 113 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 4 hours ago ⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 17 in last 7 days 🍎 Food: 0 in last 7 days 🧸 Products: 113 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 4 hours ago
🛡️ EUSW
💊 Medicines 🍎 Food 🧸 Products 🔎 Search
📊 Data
🏷 Brands 🌍 Countries ℹ️ About ✉ Unsubscribe
🇬🇧
🇬🇧 English 🇳🇱 Nederlands 🇫🇷 Français 🇩🇪 Deutsch 🇪🇸 Español 🇮🇹 Italiano 🇵🇹 Português 🇵🇱 Polski 🇸🇪 Svenska 🇷🇴 Română 🇨🇿 Čeština 🇫🇮 Suomi 🇩🇰 Dansk
💊 Medicine AT June 3, 2026

Myfortic 360 mg - magensaftresistente Filmtabletten 360 mg (magensaftresistente Tablette)

📷 EU Safety Watch placeholder
Myfortic 360 mg - magensaftresistente Filmtabletten 360 mg (magensaftresistente Tablette)
📷 EU Safety Watch placeholder
Parallel export is banned for this medicine. It is a delayed-release tablet containing 360 mg. The marketing authorisation holder is Novartis Pharma GmbH in Vienna, Austria. Affected packs are boxes of 120 tablets in blister packs, currently in limited supply since 11 May 2026, with restocking expected on 22 June 2026.
⚠️
Shortage ongoing
NATRIUM MYCOPHENOLAT is currently in short supply in AT.
📈 Timeline
14 days active so far
June 4, 2026 June 17, 2026

What is this? Myfortic is a medicine in tablet form. It helps people after an organ transplant.

What's happening? There is a short supply of Myfortic tablets. The maker cannot make enough right now.

Does this affect me? If you take Myfortic, you may have trouble getting it. This is in Austria.

What should I do? Talk to your pharmacist or doctor. They can help find a solution for you.

🤖 This plain-language summary is automatically generated from the official agency notice using AI. It is for general information only — not medical advice. For decisions about your health, always consult a pharmacist or doctor and read the official source linked below.

🔬 Medical / technical details (for professionals)
Active substance(s)
NATRIUM MYCOPHENOLAT
Agency-published detail

🚫 Parallel export ban active · ATC: L04AA06 · Reason: Verzögerung bei der Herstellung · Marketing authorisation holder: Novartis Pharma GmbH, Jakov-Lind-Straße 5/Top 3.05, 1020 Wien, Österreich · Affected packs: 120 Stück Schachtel, Blisterpackung [eingeschränkt verfügbar, since 2026-05-11, resupply 2026-06-22]

First published
June 3, 2026
Last refreshed by us
10 hours ago
Severity (as classified)
Medium
Official source
https://medikamente.basg.gv.at/en/medicine-shortage

All information on this page comes from the official agency notice. We translate and summarise it; we don't add or edit facts.

❓ Frequently asked questions

▸ What is this medicine shortage alert about?
Myfortic 360 mg - magensaftresistente Filmtabletten 360 mg (magensaftresistente Tablette). Parallel export is banned for this medicine. It is a delayed-release tablet containing 360 mg. The marketing authorisation holder is Novartis Pharma GmbH in Vienna, Austria. Affected packs are boxes of 120 tablets in blister packs, currently in limited supply since 11 May 2026, w...
▸ When was this alert issued?
This alert was issued on June 3, 2026 by BASG (Austria).
▸ Which countries are affected?
The alert applies to Austria.
▸ How serious is this alert?
Medium risk. A medium risk means harm is possible under certain conditions. Read the notice and act on the recommended steps.
▸ What should I do?
If you take this medicine, contact your pharmacist or prescribing doctor. They can advise on alternative products or substitutes. Do not stop taking prescription medicine without medical advice.
▸ Where can I find the official notice?
The full official notice is published on medikamente.basg.gv.at.

💬 Discussion

Share your experience or ask a question. Real names and email are optional but moderation friendly.

No comments yet — be the first.

We email a confirmation link. Your address stays private.

⚠️ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.